Six reported cohorts, a total of 3416 patients, were used to analyze the mutation status of ARID1A, ARID1B, ARID2 and SMARCA4 in patients with NSCLC and the effect of mutations on prognosis after ICIs....Patients with an ARID1A or ARID1B mutation treated with ICIs had a median OS (mOS) of 21 months compared to 11 months for the WT group. Patients with an ARID2 mutation treated with ICIs had an mOS of 36 months compared to 11 months for the WT group...The results of this study demonstrated that patients with ARID1A, ARID1B, or ARID2 mutations were more likely to benefit from ICIs.

Patients harboring mutated ARID family members benefited more from ICI therapy (P = .0003)….NSCLC patients harboring ARID1B mutations (P = .0415) or ARID2 (P = .0236) mutations responded better to ICI therapy than wild-type patients.

The top five altered genes, namely, ARID1A, ZFHX3, ATM, ARID2, and NTRK3, were named AZAAN. Therefore, we evaluated the effect of the predictor-AZAAN on responsive stratification in patients who had received immunotherapy. The results indicated that patients harboring AZAAN(+) received more OS benefits from immunotherapy than those patients harboring AZAAN(−) [AZAAN(+) vs. AZAAN(−): 22 months vs. 10 months, log-rank P value = 0.0006, HR = 0.59]...